Is Parnax Lab overvalued or undervalued?

As of 7 November 2025, Parnax Lab's valuation grade has moved from attractive to fair, indicating a shift in market perception. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 13.60, an EV to EBITDA of 8.35, and a ROE of 13.86%.
In comparison to peers, Parnax Lab's PE ratio is significantly lower than Elitecon International, which is considered very expensive at 378.62, and MMTC, which is also risky at 139.02. This suggests that while Parnax Lab is fairly valued, it remains more attractive relative to some peers in the pharmaceuticals and biotechnology sector. Over the past year, Parnax Lab has underperformed the Sensex, with a return of -29.90% compared to the Sensex's 4.62%, reinforcing the notion that it may be a more stable investment compared to its more volatile peers.